Overall survival for renal cell carcinoma after radical nephrectomy is 50% at 5 years. This poor prognosis is related especially to the stage of disease, having a major predictor of progression, positive lymph nodes or a tumor beyond the renal capsule. In this study, the role has been investigated of adjuvant therapy with Interferon or Interferon + Vinblastine to decrease the risk of progression. Preliminary results on the toxicity of this regimen are presented. Of 12 patients treated (6 with Interferon and 6 with Interferon + Vinblastine), none reached WHO grade 3 toxicity. Major side effects were leukopenia, paraesthesia, fever, chills and headache, resolved with medical treatment or suspension therapy. However, regimen interruption was never prolonged over 3 weeks. It is concluded that this form of adjvuant regimen is tolerable and can be safety administered in patients with advanced renal cell carcinoma.
|Translated title of the contribution||Preliminary results of the association recombinant alpha 2a-interferon and vinblastine in the adjuvant therapy of renal carcinoma in the locally advanced stage|
|Number of pages||3|
|Journal||Acta Urologica Italica|
|Publication status||Published - 1992|
ASJC Scopus subject areas